SALT LAKE CITY — Defibrotide benefitted adults and pediatric patients with severe or very severe veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation, according to study results.
The findings of the DEFIFrance study — presented at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR — align with previous studies that supported use of the agent in this setting.
“The DEFIFrance study represents the largest collection of real-world data on post-registration use of defibrotide,” Mohamad